Dihydroergotamine — Membership Pricing

Other medications in Pain & Inflammation

• Eletriptan
• Ergotamine
• Etodolac
• Fenoprofen
• Flurbiprofen
• Frovatriptan
• Hydrocodone
• Hydrocodone-Acetaminophen

About Dihydroergotamine

Dihydroergotamine (DHE) is a prescription medication often used to treat acute migraine attacks, providing relief when a migraine strikes. If you or a loved one relies on DHE, understanding your options for cost savings is crucial. TheDrugClub membership can help you navigate prescription prices and access potential benefits, making your essential medications more affordable.

What is Dihydroergotamine and What Does it Treat?

Dihydroergotamine (DHE) is a medication primarily prescribed for the acute treatment of migraine headaches. Unlike medications designed to prevent migraines, DHE is taken once a migraine attack has already started. It can be particularly effective for individuals who haven't found sufficient relief with other migraine treatments, or for those whose migraines are often accompanied by severe nausea and vomiting. DHE is available in different forms, including nasal sprays and injectable solutions, allowing for flexible administration based on individual needs and severity of symptoms. It's important to note that DHE is not intended for the prevention of migraines or for the treatment of common tension headaches.

How Does Dihydroergotamine Work?

DHE belongs to a class of drugs known as ergot alkaloids. Its mechanism of action involves interacting with specific serotonin receptors (5-HT1B and 5-HT1D) in the brain. When a migraine occurs, blood vessels in the brain can become dilated and inflamed, contributing to the throbbing pain. DHE works by causing these cranial blood vessels to constrict, reducing the painful pulsations. Additionally, it helps to block the release of certain chemicals that promote inflammation and pain in the brain, further alleviating migraine symptoms. This dual action makes DHE a potent option for quickly aborting an ongoing migraine attack.

Typical Costs of Dihydroergotamine

The cost of dihydroergotamine can vary significantly depending on its formulation (nasal spray versus injectable), dosage, and the pharmacy where it's purchased. Without insurance, a single dose or a package containing several doses can range from hundreds to even over a thousand dollars, making it a substantial expense for many patients. These high costs can be a barrier to accessing necessary treatment, highlighting the importance of exploring all available savings options. Prices can

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dihydroergotamine is approved for (FDA label)

TRUDHESA is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use TRUDHESA is not indicated for the preventive treatment of migraine. TRUDHESA is not indicated for the management of hemiplegic or basilar migraine. TRUDHESA is an ergotamine derivative indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use: TRUDHESA is not indicated for the preventive treatment of migraine or for the management of hemiplegic or basilar migraine. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Dihydroergotamine (FDA label)

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of TRUDHESA with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) , Warnings and Precautions (5.1) , and Drug Interactions (7.1) ]. WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS See full prescribing information for complete boxed warning. Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of TRUDHESA with strong CYP3A4 inhibitors is contraindicated. ( 4 , 5.1 , 7.1 )

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dihydroergotamine (FDA label)

TRUDHESA (dihydroergotamine mesylate) nasal spray is a single-dose, drug-device combination product containing a vial of dihydroergotamine mesylate with a clear and colorless to faintly yellow solution and an intranasal delivery device. Each spray delivers 0.725 mg of dihydroergotamine mesylate. Nasal spray: 0.725 mg dihydroergotamine mesylate per spray. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dihydroergotamine (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Peripheral Ischemia Following Coadministration with Strong CYP3A4 Inhibitors [see Boxed Warning and Warnings and Precautions (5.1) ] Myocardial Ischemia and/or Infarction, Other Adverse Cardiac Events, and Fatalities [see Warnings and Precautions (5.2) ] Cerebrovascular Adverse Reactions and Fatalities [see Warnings and Precautions (5.3) ] Other Vasospasm Related Adverse Reactions [see Warnings and Precautions (5.4) ] Increase in Blood Pressure [see Warnings and Precautions (5.5) ] Medication Overuse Headache [see Warnings and Precautions (5.6) ] Preterm Labor [see Warnings and Precautions (5.7) ] Fibrotic Complications [see Warnings and Precautions (5.8) ] Local Irritation [see Warnings and Precautions (5.9) ] Most common adverse reactions (greater than 1%) were rhinitis, nausea, altered sense of taste, application site reactions, dizziness, vomiting, somnolence, pharyngitis, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Impel Pharmaceuticals LLC at 1-833-878-3437 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dihydroergotamine (FDA label)

TRUDHESA is contraindicated in patients: with concomitant use of strong CYP3A4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, or indinavir), macrolide antibiotics (e.g., erythromycin or clarithromycin), and antifungals (ketoconazole or itraconazole) [see Warnings and Precautions (5.1) and Drug Interactions (7.1) ] with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina [see Warnings and Precautions (5.4) ] with uncontrolled hypertension [see Warnings and Precautions (5.5) ] with peripheral arterial disease with sepsis following vascular surgery with severe hepatic impairment with severe renal impairment with known hypersensitivity to ergot alkaloids with recent use (i.e., within 24 hours) of other 5-HT 1 agonists (e.g., sumatriptan) or ergotamine-containing or ergot-type medications [see Drug Interactions (7.2) ] with concomitant use of peripheral and central vasoconstrictors because the combination may result in additive

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dihydroergotamine (FDA label)

Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities: In patients with risk factors, consider 1 st dose administration under medical supervision with electrocardiogram. ( 2.2 , 5.2 ) Cerebrovascular Adverse Reactions and Fatalities: Cerebral hemorrhage, subarachnoid hemorrhage and stroke have been reported; discontinue TRUDHESA if suspected. ( 5.3 ) Other Vasospasm Related Adverse Reactions: TRUDHESA may cause vasospasm or elevation in blood pressure. Discontinue if signs or symptoms of vasoconstriction develop. ( 5.4 , 5.5 ) Medication Overuse Headache: Detoxification may be necessary. ( 5.6 ) Preterm Labor: Advise pregnant women of the risk. ( 5.7 , 8.1 ) Fibrotic Complications: Pleural and retroperitoneal fibrosis have been reported following prolonged daily use of dihydroergotamine mesylate.

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dihydroergotamine (FDA label)

Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction ( 7.3 , 7.5 ) Selective Serotonin Reuptake Inhibitors: Weakness, hyperreflexia, and incoordination may occur with coadministration. ( 7.6 ) 7.1 CYP3A4 Inhibitors There have been rare reports of serious adverse events in connection with the coadministration of intravenous administration of dihydroergotamine and strong CYP3A4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, indinavir), macrolide antibiotics (e.g., erythromycin, clarithromycin), and antifungals (e.g., ketoconazole, itraconazole), resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities [see Warnings and Precautions (5.1) ]. The use of strong CYP3A4 inhibitors with dihydroergotamine is contraindicated [see Contraindications (4) ] . Administer moderate CYP3A4 inhibitors (e.g., saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, clotrimazole) with caution. 7.2 Triptans Triptans (serotonin [5-HT] 1B/1D receptor agonists) have been reported to cause coronary artery vasospasm, and its effect could be additive with TRUDHESA. Therefore, triptans and TRUDHESA should not be

Source: FDA prescribing information (DailyMed). Set ID: b81397b0-910d-4eb4-8fee-a9a3c9d94d63. SPL document ID: ff3340ed-c740-497d-9959-c369049030d0. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.